Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ADMA Biologics stock

ADMA
US0008991046
A12FAG

Price

19.99
Today +/-
+0.54
Today %
+3.07 %
P

ADMA Biologics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ADMA Biologics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ADMA Biologics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ADMA Biologics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ADMA Biologics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ADMA Biologics Stock Price History

DateADMA Biologics Price
9/30/202419.99 undefined
9/27/202419.39 undefined
9/26/202419.44 undefined
9/25/202419.49 undefined
9/24/202419.29 undefined
9/23/202420.03 undefined
9/20/202419.98 undefined
9/19/202419.74 undefined
9/18/202419.32 undefined
9/17/202418.71 undefined
9/16/202418.20 undefined
9/13/202418.09 undefined
9/12/202417.65 undefined
9/11/202416.91 undefined
9/10/202417.29 undefined
9/9/202418.38 undefined
9/6/202416.26 undefined
9/5/202416.74 undefined
9/4/202416.87 undefined
9/3/202416.57 undefined

ADMA Biologics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ADMA Biologics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ADMA Biologics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ADMA Biologics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ADMA Biologics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ADMA Biologics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ADMA Biologics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ADMA Biologics’s growth potential.

ADMA Biologics Revenue, EBIT and net profit per share

DateADMA Biologics RevenueADMA Biologics EBITADMA Biologics Net Income
2029e591.29 M undefined0 undefined164.04 M undefined
2028e554.83 M undefined213.95 M undefined154.53 M undefined
2027e529.07 M undefined205.53 M undefined167.61 M undefined
2026e554.57 M undefined187.58 M undefined171.17 M undefined
2025e470.44 M undefined152.34 M undefined158.5 M undefined
2024e413.87 M undefined102.7 M undefined116.49 M undefined
2023258.22 M undefined23.73 M undefined-28.24 M undefined
2022154.1 M undefined-39.3 M undefined-65.9 M undefined
202180.9 M undefined-58.4 M undefined-71.6 M undefined
202042.2 M undefined-64.9 M undefined-75.7 M undefined
201929.3 M undefined-41.4 M undefined-48.3 M undefined
201817 M undefined-60.3 M undefined-65.7 M undefined
201722.8 M undefined-38.4 M undefined-43.8 M undefined
201610.7 M undefined-17.3 M undefined-19.5 M undefined
20157.2 M undefined-15.5 M undefined-18 M undefined
20145.9 M undefined-16 M undefined-16.8 M undefined
20133.1 M undefined-15 M undefined-15.5 M undefined
20121.1 M undefined-7.9 M undefined-7.3 M undefined
2011800,000 undefined-4.6 M undefined-5.9 M undefined
20100 undefined-5.5 M undefined-5.9 M undefined

ADMA Biologics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
001357102217294280154258413470554529554591
---200.0066.6740.0042.86120.00-22.7370.5944.8390.4892.5067.5360.0813.8017.87-4.514.736.68
---33.3340.0028.5740.00-27.27-147.06-34.48-45.241.2522.7335.27------
0-101224-6-25-10-1913591000000
-5-4-7-15-16-15-17-38-60-41-64-58-39231021521872052130
---700.00-500.00-320.00-214.29-170.00-172.73-352.94-141.38-152.38-72.50-25.328.9124.7032.3433.7538.7538.45-
-5-5-7-15-16-18-19-43-65-48-75-71-65-28116158171167154164
--40.00114.296.6712.505.56126.3251.16-26.1556.25-5.33-8.45-56.92-514.2936.218.23-2.34-7.786.49
2.435.36.59.310.412.222.945.254.386.1139.6197.9223.98000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The ADMA Biologics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ADMA Biologics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20102011201220132014201520162017201820192020202120222023
                           
0.20.112.529.121.916.815.343.122.826.855.951.186.551.35
00000.40.913.91.43.513.228.615.527.42
00000000000000
3.41.11.31.71.73.4512.618.653.181.5124.7163.3172.91
0.10.10.10.30.10.10.32.71.82.534.35.15.33
3.71.313.931.124.121.221.662.344.685.9153.6208.7270.4257.01
1.10.90.80.82.82.4230.530.133.145.958.268.763.47
40030050000000000000
00000000000000
00000004.843.22.41.710.5
00000003.53.53.53.53.53.53.53
00.40.40.20.1006.86.71.42.14.14.84.67
1.51.61.712.92.4245.644.341.253.967.57872.17
5.22.915.632.12723.623.6107.988.9127.1207.5276.2348.4329.18
                           
000000000000023
2030.246.574.275.588.2102.5191236.2290.9428.7553.3630641.44
-23.9-29.8-37.1-52.6-69.4-87.4-106.9-150.7-216.4-264.7-340.5-412.1-478-506.26
00000000000000
00000000000000
-3.90.49.421.66.10.8-4.440.319.826.288.2141.2152135.21
0.81.31.12.71.82.12.65.95.99.211.112.413.215.66
0.90.50.70.92.322.43.43.64.78.716.824.131.05
0000.10.10.10.10.10.10.10.11.21.93.09
00000000000000
7.10.500006.10000000
8.82.31.83.74.24.211.29.49.61419.930.439.249.81
0.10.14.25.115.215.714.14344.183.29394.9142.8130.59
00000000000000
0.20.10.11.71.632.815.315.43.76.59.814.413.58
0.30.24.36.816.818.716.958.359.586.999.5104.7157.2144.17
9.12.56.110.52122.928.167.769.1100.9119.4135.1196.4193.98
5.22.915.532.127.123.723.710888.9127.1207.6276.3348.4329.18
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ADMA Biologics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ADMA Biologics's financial health and stability.

Assets

ADMA Biologics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ADMA Biologics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ADMA Biologics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ADMA Biologics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20102011201220132014201520162017201820192020202120222023
-5-5-7-15-16-17-19-43-65-48-75-71-65-28
00000002333578
00000000000000
020300-10-3-33-33-51-18-10
0111243554682245
000001124810111318
00000000000000
-4-1-6-10-14-15-18-37-62-76-102-112-598
0000-200-2-2-3-12-13-13-4
000-3-4-1015-2-3-12-13-13-4
000-2-1-1017000000
00000000000000
21309032404213051-23
00172701014394248131121641
21192791016604280143121108-38
---1.00----1.00-3.00--10.00---7.00-16.00
00000000000000
-201213-8-6038-21029-435-35
-4.81-1.43-7.02-11.09-17.02-15.45-18.34-39.95-64.78-80-114.73-125.88-73.423.82
00000000000000

ADMA Biologics stock margins

The ADMA Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ADMA Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ADMA Biologics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ADMA Biologics's sales revenue. A higher gross margin percentage indicates that the ADMA Biologics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ADMA Biologics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ADMA Biologics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ADMA Biologics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ADMA Biologics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ADMA Biologics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ADMA Biologics Margin History

ADMA Biologics Gross marginADMA Biologics Profit marginADMA Biologics EBIT marginADMA Biologics Profit margin
2029e35.26 %0 %27.74 %
2028e35.26 %38.56 %27.85 %
2027e35.26 %38.85 %31.68 %
2026e35.26 %33.82 %30.87 %
2025e35.26 %32.38 %33.69 %
2024e35.26 %24.81 %28.15 %
202335.26 %9.19 %-10.94 %
202222.91 %-25.5 %-42.76 %
20211.48 %-72.19 %-88.5 %
2020-45.26 %-153.79 %-179.38 %
2019-34.81 %-141.3 %-164.85 %
2018-148.24 %-354.71 %-386.47 %
2017-28.07 %-168.42 %-192.11 %
201640.19 %-161.68 %-182.24 %
201540.28 %-215.28 %-250 %
201437.29 %-271.19 %-284.75 %
201332.26 %-483.87 %-500 %
201236.36 %-718.18 %-663.64 %
2011-175 %-575 %-737.5 %
201035.26 %0 %0 %

ADMA Biologics Stock Sales Revenue, EBIT, Earnings per Share

The ADMA Biologics earnings per share therefore indicates how much revenue ADMA Biologics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ADMA Biologics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ADMA Biologics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ADMA Biologics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ADMA Biologics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ADMA Biologics Revenue, EBIT and net profit per share

DateADMA Biologics Sales per ShareADMA Biologics EBIT per shareADMA Biologics Earnings per Share
2029e2.54 undefined0 undefined0.7 undefined
2028e2.38 undefined0 undefined0.66 undefined
2027e2.27 undefined0 undefined0.72 undefined
2026e2.38 undefined0 undefined0.73 undefined
2025e2.02 undefined0 undefined0.68 undefined
2024e1.78 undefined0 undefined0.5 undefined
20231.15 undefined0.11 undefined-0.13 undefined
20220.78 undefined-0.2 undefined-0.33 undefined
20210.58 undefined-0.42 undefined-0.51 undefined
20200.49 undefined-0.75 undefined-0.88 undefined
20190.54 undefined-0.76 undefined-0.89 undefined
20180.38 undefined-1.33 undefined-1.45 undefined
20171 undefined-1.68 undefined-1.91 undefined
20160.88 undefined-1.42 undefined-1.6 undefined
20150.69 undefined-1.49 undefined-1.73 undefined
20140.63 undefined-1.72 undefined-1.81 undefined
20130.48 undefined-2.31 undefined-2.38 undefined
20120.21 undefined-1.49 undefined-1.38 undefined
20110.27 undefined-1.53 undefined-1.97 undefined
20100 undefined-2.29 undefined-2.46 undefined

ADMA Biologics business model

ADMA Biologics is a leading company in the development and manufacturing of biological therapies for the treatment of serious diseases. The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics' business model is based on the development and manufacturing of specialized biological therapies tailored to the needs of patients with rare diseases and severe infections. It specializes in the development of plasma-based therapies to treat patients with immune deficiency and autoimmune diseases, hemophilia, and severe blood loss due to trauma or surgery. ADMA Biologics' products include intravenously administered immune globulin (IVIG) called BIVIGAM, approved for intravenous infusion in patients with primary immune deficiency or other immune disorders. CyclASol, an eye drop for patients with the eye inflammation Keratoconjunctivitis Sicca, is also a product developed by ADMA Biologics. Additionally, ADMA Biologics is currently expanding its product portfolio through the development of PDIG, a product in phase III clinical trial for the treatment of secondary immune deficiencies. The company has long-standing partnerships with other companies and organizations in the industry to combine its resources and expertise in the development and marketing of innovative therapies. ADMA Biologics also operates its own plasma collection center to ensure the supply of plasma for its therapies. In terms of its divisions, ADMA Biologics currently focuses on the USA, where the company offers its products through a dedicated sales team. Additionally, ADMA Biologics aims to expand its presence worldwide by introducing its products into new regions and markets. The company has achieved important regulatory milestones in Europe and other parts of the world, including the approval of BIVIGAM's sale in Korea and the Industrial Ministry Jubilee Memorial for BIVIGAM's introduction in Japan. ADMA Biologics' history began in 2004 when the company specialized in the development and manufacturing of plasma-based therapies for patients with rare diseases. In 2009, the company received its first FDA approval for ASCENIV, an immune globulin product for the treatment of immune deficiency disorders. In 2011, ADMA Biologics acquired a plasma collection center to expand its resources and capabilities and ensure an independent supply chain for plasma. Since then, the company has gained importance in the industry through the development and introduction of innovative products and therapies. In 2018, ADMA Biologics established a subsidiary in Germany to support the company's expansion into the European continent. In the same year, the company also obtained FDA approval in the United States for BIVIGAM, the first IVIG product manufactured from human plasma in the country. Overall, ADMA Biologics has a strong brand presence in the industry and is successfully expanding its portfolio of plasma-based therapies. The company has established strong partnerships with organizations in the industry to jointly develop and bring innovative solutions to a wide range of diseases. ADMA Biologics has a very positive future outlook and is expected to play a significant role in the field of biological therapies by continuing to develop and bring innovative therapies to the market. ADMA Biologics is one of the most popular companies on Eulerpool.com.

ADMA Biologics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

ADMA Biologics Revenue by Segment

Segmente2023202220212020201920182017201620152014
Product Revenue-153.94 M U00180.8 M U001-------
License Revenue-142,834 U001142,834 U001-------
ADMA BioManufacturing---36.67 M U00122.18 M U0016.8 M U00110.98 M U001---
Plasma Collection Centers---5.4 M U0017.03 M U00110.04 M U00111.64 M U00110.52 M U0017.05 M U001-
Consolidated (member)---42.22 M U001------
Plasma Collection Center---------5.84 M U001
Corporate143,000 U001142,834 U001142,834 U001142,834 U001142,834 U001142,834 U001142,834 U001142,834 U001127,350 U00175,556 U001
Research And Development----------

ADMA Biologics Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

ADMA Biologics Revenue by Segment

DateInternationalUnited States
202313.33 M U001244.88 M U001
20227.65 M U001146.43 M U001
202110.32 M U00170.63 M U001

ADMA Biologics SWOT Analysis

Strengths

ADMA Biologics Inc possesses a robust intellectual property portfolio, which provides a significant competitive advantage in the biologics industry. This comprehensive IP portfolio protects their innovative products and technologies, making it difficult for competitors to replicate or infringe upon their advancements.

ADMA Biologics Inc has state-of-the-art manufacturing facilities and a well-established production process. Their advanced manufacturing capabilities enable them to efficiently produce high-quality biologics, streamlining the supply chain and ensuring consistent product availability to meet market demands.

Weaknesses

ADMA Biologics Inc heavily relies on a single manufacturing facility for their production, which poses a potential vulnerability to their supply chain. Any disruption or operational issues at the facility could negatively impact their ability to meet market demand and fulfill orders in a timely manner.

Currently, ADMA Biologics Inc has a relatively limited product portfolio, focusing primarily on immune globulin products. This narrower range of offerings may limit their revenue potential and leave them more vulnerable to market fluctuations or competition in the biologics industry.

Opportunities

ADMA Biologics Inc can capitalize on the growing global biologics market by expanding their product offerings and entering new market segments. By diversifying their portfolio, they can target a broader customer base and enhance their revenue potential while taking advantage of increasing demand for biologic therapies worldwide.

Investing in research and development to develop new products and innovative therapies can open up new revenue streams for ADMA Biologics Inc. By focusing on expanding their pipeline, they can stay ahead of competitors and address unmet medical needs, positioning themselves as a leading player in the biologics market.

Threats

The biologics industry is highly competitive with numerous established players and new entrants. ADMA Biologics Inc faces the risk of increased competition, pricing pressures, and potential loss of market share if they fail to differentiate their products effectively or keep up with technological advancements and industry trends.

As a biologics company, ADMA Biologics Inc is subject to rigorous regulatory requirements and quality control standards. Any failure to comply with these regulations or maintaining proper documentation can result in regulatory penalties, product recalls, damage to reputation, and potential legal action, posing a significant threat to their operations and financial stability.

ADMA Biologics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ADMA Biologics historical P/E ratio, EBIT multiple, and P/S ratio

ADMA Biologics shares outstanding

The number of shares was ADMA Biologics in 2023 — This indicates how many shares 223.977 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ADMA Biologics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ADMA Biologics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ADMA Biologics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ADMA Biologics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for ADMA Biologics.

ADMA Biologics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.08 0.13  (59.31 %)2024 Q2
3/31/20240.06 0.08  (42.6 %)2024 Q1
12/31/20230.03 -0.08  (-413.73 %)2023 Q4
9/30/2023-0.01 0.01  (229.87 %)2023 Q3
6/30/2023-0.03 -0.03  (-17.65 %)2023 Q2
3/31/2023-0.04 -0.03  (30.88 %)2023 Q1
12/31/2022-0.06 -0.06  (5.96 %)2022 Q4
9/30/2022-0.08 -0.08  (-1.14 %)2022 Q3
6/30/2022-0.08 -0.07  (14.22 %)2022 Q2
3/31/2022-0.09 -0.1  (-15.34 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the ADMA Biologics stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

29

👫 Social

42

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ADMA Biologics shareholders

%
Name
Stocks
Change
Date
6.99582 % BlackRock Institutional Trust Company, N.A.16,305,8531,214,67012/31/2023
5.51274 % The Vanguard Group, Inc.12,849,091110,18012/31/2023
4.06881 % State Street Global Advisors (US)9,483,590-118,34812/31/2023
3.95685 % Stonepine Capital Management, LLC9,222,617118,34212/31/2023
2.92290 % American Century Investment Management, Inc.6,812,6911,920,56812/31/2023
2.79456 % D. E. Shaw & Co., L.P.6,513,553-1,058,14012/31/2023
2.76015 % Perceptive Advisors LLC6,433,369-550,95012/31/2023
2.69990 % Nuveen LLC6,292,932213,55712/31/2023
2.69545 % Magnetar Capital Partners LP6,282,556408,37812/31/2023
2.57417 % AWM Investment Company, Inc.5,999,872012/31/2023
1
2
3
4
5
...
10

ADMA Biologics Executives and Management Board

Mr. Adam Grossman46
ADMA Biologics President, Chief Executive Officer, Co-Founder, Director (since 2007)
Compensation 2.65 M
Mr. Brian Lenz50
ADMA Biologics Chief Financial Officer, Executive Vice President
Compensation 1.6 M
Mr. Steven Elms59
ADMA Biologics Independent Chairman of the Board
Compensation 182,882
Dr. Jerrold Grossman75
ADMA Biologics Vice Chairman of the Board, Co-Founder
Compensation 177,382
Mr. Bryant Fong50
ADMA Biologics Independent Director
Compensation 175,507
1
2

ADMA Biologics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer0,67-0,250,650,880,350,57
Grifols A Stock
Grifols A
SupplierCustomer0,30-0,070,48-0,01-0,190,60
1

Most common questions regarding ADMA Biologics

What values and corporate philosophy does ADMA Biologics represent?

ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.

In which countries and regions is ADMA Biologics primarily present?

ADMA Biologics Inc is primarily present in the United States.

What significant milestones has the company ADMA Biologics achieved?

ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.

What is the history and background of the company ADMA Biologics?

ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide. Note: The provided answer is only for reference purposes and should be tailored or reviewed according to the specific requirements or guidelines provided by the professional stock website.

Who are the main competitors of ADMA Biologics in the market?

The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.

In which industries is ADMA Biologics primarily active?

ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.

What is the business model of ADMA Biologics?

ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.

What is the P/E ratio of ADMA Biologics 2024?

The ADMA Biologics P/E ratio is 38.43.

What is the P/S ratio of ADMA Biologics 2024?

The ADMA Biologics P/S ratio is 10.82.

What is the AlleAktien quality score of ADMA Biologics?

The AlleAktien quality score for ADMA Biologics is 4/10.

What is the revenue of ADMA Biologics 2024?

The expected ADMA Biologics revenue is 413.87 M USD.

How high is the profit of ADMA Biologics 2024?

The expected ADMA Biologics profit is 116.49 M USD.

What is the business model of ADMA Biologics

ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.

What is the ADMA Biologics dividend?

ADMA Biologics pays a dividend of 0 USD distributed over payouts per year.

How often does ADMA Biologics pay dividends?

The dividend cannot currently be calculated for ADMA Biologics or the company does not pay out a dividend.

What is the ADMA Biologics ISIN?

The ISIN of ADMA Biologics is US0008991046.

What is the ADMA Biologics WKN?

The WKN of ADMA Biologics is A12FAG.

What is the ADMA Biologics ticker?

The ticker of ADMA Biologics is ADMA.

How much dividend does ADMA Biologics pay?

Over the past 12 months, ADMA Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADMA Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADMA Biologics?

The current dividend yield of ADMA Biologics is .

When does ADMA Biologics pay dividends?

ADMA Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADMA Biologics?

ADMA Biologics paid dividends every year for the past 0 years.

What is the dividend of ADMA Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADMA Biologics located?

ADMA Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADMA Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADMA Biologics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did ADMA Biologics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of ADMA Biologics in the year 2023?

In the year 2023, ADMA Biologics distributed 0 USD as dividends.

In which currency does ADMA Biologics pay out the dividend?

The dividends of ADMA Biologics are distributed in USD.

All fundamentals about ADMA Biologics

Our stock analysis for ADMA Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADMA Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.